Business Information
The company's principal activity is the research and development of synthetic solutions used during low temperature surgery and organ preservation solutions. The products enable the substitution of blood plasma volume expanders and blood replacement solutions during the hypothermic surgery. Currently in its development stages, the company is also developing a specially formulated hypothermic blood for the replacement of very large volumes of a patient's blood during cardiac surgery, neurosurgery and other surgeries. Hextend (TM), the first product of the company is a physiologically balanced blood plasma volume expander, for the treatment of hypovolemia. The company is also developing pentalyte, a penta-starch based synthetic plasma expander and hetacool, a modified formulation of hextend specifically designed for use at low temperatures. It has provided an exclusive license to abbott laboratories to manufacture and sell hextend.
|
|
Name |
Title
|
Email
|
| Steven Seinberg | CFO, Treasurer | N/A | | Hal Sternberg | Dir., VP - Research | N/A | | Harold Waitz | Dir., VP - Engineering, Regulatory Affairs, Office, Pres. | N/A | | Jeffrey Nickel | VP - Business Development, Marketing | N/A | | Judith Segall | Dir., VP - Operations, Corp. Sec, Pres. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,162 | (1,865) | | 2005 | 903 | (2,074) | | 2004 | 688 | (3,085)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
